Editorials

Selective serotonin reuptake inhibitors and congenital malformations

BMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3525 (Published 23 September 2009) Cite this as: BMJ 2009;339:b3525
  1. Christina Chambers, associate professor
  1. 1Division of Dysmorphology and Teratology, Departments of Pediatrics and Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0828, La Jolla, CA 92093-0828, USA
  1. chchambers{at}ucsd.edu

    The small risk of harm must be balanced against risk of suboptimal or no treatment

    Major depressive disorder in women is most common during their childbearing years, and about 13% of women in the United States have taken an antidepressant drug during pregnancy.1 2 In the past 20 years, selective serotonin reuptake inhibitors (SSRIs) have become a mainstay of treatment in women with major depressive disorder; however, concerns persist about safety for the developing fetus. This is counterbalanced by equally compelling concerns about the consequences of undertreatment for mother and child.3

    In the linked population based cohort study from Denmark (doi:10.1136/bmj.b3569), Pedersen and colleagues confirm a previously reported doubling of risk for septal heart defects after early exposure in pregnancy to SSRIs (odds ratio 1.99, 95% confidence interval 1.12 to 3.53).4 However, in contrast to previous studies, redemptions of prescriptions for citalopram and sertraline, but not paroxetine or fluoxetine, were significantly associated with this …

    Sign in

    Subscribe